Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 12,548 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors, Epidemiology, Chronic Kidney Disease(CKD), Hypertension
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 0 Minutes to 2 Weeks
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 53
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 48 more

Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration; Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1201
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more

Conditions: Type 1 Diabetes Mellitus, Hypoglycemia, Hypoglycemia Unawareness
Interventions: Islet transplantation; Biological
Lead sponsor: Rodolfo Alejandro; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Disease Progression, Brain Atrophy
Interventions: Tcelna, Placebo; Biological
Lead sponsor: Opexa Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 28 more

Conditions: Parkinson's Disease (PD)
Interventions: ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 70
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more

Conditions: Thymoma and Thymic Carcinoma
Interventions: octreotide acetate, prednisone; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 24
States / cities: Palo Alto, California • Stanford, California • Denver, Colorado + 18 more

Conditions: Partial Epilepsies
Interventions: lacosamide; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: Not listed
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 40 more

Conditions: Lymphoma
Interventions: Duvelisib, Rituximab, R-CHOP, Prednisone; Drug
Lead sponsor: SecuraBio; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Gastroesophageal Reflux
Interventions: pantoprazole; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 1 Day to 12 Months
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 45
States / cities: Phoenix, Arizona • Loma Linda, California • Oakland, California + 42 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo, Dexpramipexole 50 mg/day, Dexpramipexole 150 mg/day, Dexpramipexole 300 mg/day; Drug
Lead sponsor: Knopp Biosciences; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 18 more

Conditions: Anesthesia, Surgical Procedures, Elective
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 27
States / cities: Birmingham, Alabama • Loma Linda, California • Miami, Florida + 18 more

Conditions: Hiv, Violence
Interventions: WMR; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Heart Transplant Rejection, Immune Suppression, Pediatric Heart Transplant, Medication Nonadherence, Health Behavior, Remote Monitoring, Patient Engagement
Interventions: DOT intervention; Other
Lead sponsor: University of Florida; Other
Eligibility: 10 Years to 21 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Coral Gables, Florida • Gainesville, Florida • Hollywood, Florida + 1 more

Conditions: Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML
Interventions: CLN-049; Drug
Lead sponsor: Cullinan Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 13 more

Conditions: Healthy Volunteers
Interventions: Amlitelimab DP1, Amlitelimab DP2; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Lung Cancer
Interventions: BCG vaccine, monoclonal antibody BEC2; Biological
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 34
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 29 more

Conditions: Major Depressive Disorder
Interventions: Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 1,522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 35
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: COPD, Smoking, Tobacco Use
Interventions: THS use, Cigarette, Smoking Abstinence; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 715 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 81
States / cities: Brandon, Florida • Cape Coral, Florida • Clearwater, Florida + 41 more

Conditions: Chorea, Huntington
Interventions: Valbenazine, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 42
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Diabetic Foot Ulcers
Interventions: PRP Concepts Fibrin Bio-Matrix, Usual and Customary Practice; Device · Other
Lead sponsor: PRP Concepts, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pre-Exposure Prophylaxis of HIV-1 Infection
Interventions: F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 5,399 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 54
States / cities: Beverly Hills, California • Los Angeles, California • Newport Beach, California + 38 more

Conditions: Aortic Coarctation
Interventions: Treatment of Aortic Wall Injury; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 19
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 16 more

Conditions: Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions: Memantine Hydrochloride (HCl); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 906 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 72
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more

Conditions: Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions: Ampreloxetine; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Search by objective public record fields.

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Allogeneic Islet Cells Transplanted Onto the Omentum

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)

Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)

A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation During Monitored Anesthesia Care (MAC)

Within My Reach (WMR) Adaptation

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants

Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

VA Augmentation and Switching Treatments for Improving Depression Outcomes

Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Non-Healing Diabetic Foot Ulcers

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855